Document:

Amendment No.1 to the Amended and Restated Registration Right Agreement

 EXHIBIT 10.6 
 AMENDMENT NO. 1 TO AMENDED AND RESTATED REGISTRATION RIGHTS 
 AGREEMENT

 This AMENDMENT NO.1 (this “Amendment”) TO THE AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT
is entered into as of May 25, 2012, by and between Lighting Science Group Corporation, a Delaware corporation (the “Company”), and Pegasus Partners IV, L.P. (the “Investor”) and amends that
certain Amended and Restated Registration Rights Agreement, dated as of January 23, 2009, by and between the Company and the Investor (the “Registration Rights Agreement”). This Amendment clarifies and implements the
intent of the Registration Rights Agreement. 
  

	 	1.	The first reference to the “Company” in Section 2.1.3 of the Registration Rights Agreement should be read as “the Investor or any Pegasus
Party.” 

  

	 	2.	The following definitions shall be added, in the appropriate alphabetical order, to Section 1 of the Registration Rights Agreement: 

“Equity Securities” means (i) any capital stock or other share capital; (ii) any securities directly or
indirectly convertible into or exchangeable for any capital stock or other share capital or containing any profit participation features; (iii) any rights or options directly or indirectly to subscribe for or to purchase any capital stock,
other share capital or securities containing any profit participation features or to subscribe for or to purchase any securities directly or indirectly convertible into or exchangeable for any capital stock, other share capital or securities
containing any profit participation features; or (iv) any securities issued or issuable with respect to the securities referred to in clauses (i) through (iii) above in connection with a combination of shares, exchange,
recapitalization, merger, consolidation or other reorganization. 
 “Following Holdback Period” is
defined in Section 6.1. 
 “Geveran Shares” means all of the securities that could be requested to
be included in any registration pursuant to that certain Registration Rights Agreement, dated as of June 6, 2011, by and between the Company and Geveran Investments Ltd. 
 “Holdback Extension” is defined in Section 6.1. 

“Home Depot Shares” means all of the securities that could be requested to be included in any registration
pursuant to that certain Registration Rights Agreement, dated as of January 14, 2011, by and between the Company and The Home Depot, Inc. 
 “Joint Demand Registration” is defined in Section 2.1.5. 
 “Joint Notice” is defined in Section 2.1.5. 

“Marketed Underwritten Shelf Take-Down” means an Underwritten Shelf Take-Down involving a customary “road
show” (including an “electronic road show”) or other substantial marketing effort by one or more Underwriters. 

 “Non-Marketed Underwritten Shelf Take-Down” means any Underwritten
Shelf Take-Down that does not constitute a Marketed Underwritten Shelf Take-Down. 
 “Pegasus Shares” is
defined in Section 2.1.5. 
 “Public Offering” means the sale of the Company’s Common Stock for
cash to the public pursuant to an effective Registration Statement filed under the Securities Act. 
 “QPO Holdback
Period” is defined in Section 6.1. 
 “Qualified Public Offering” means the sale of the
Company’s Common Stock for cash to the public pursuant to an effective Registration Statement filed under the Securities Act, such sale to be pursuant to a firmly committed underwritten Public Offering of the Common Stock on The NASDAQ Stock
Market or the New York Stock Exchange, where (a) the gross proceeds received by the Company and any selling stockholders in the offering are no less than $100,000,000 and (b) the market capitalization of the Company immediately after
consummation of the offering is no less than $500,000,000. 
 “Recipients” is defined in
Section 2.1.5. 
 “Riverwood Shares” means all of the securities that could be requested to be
included in any registration pursuant to that certain Registration Rights Agreement, dated as of May 25, 2012, by and among the Company, RW LSG Holdings LLC and RW LSG Management Holdings LLC (the “Riverwood Registration Rights
Agreement”). 
 “Sale Transaction” is defined in Section 6.1. 

“Senders” is defined in Section 2.1.5. 

“Shelf Take-Down” is defined in Section 2.3. 

“Underwritten Shelf Take-Down” means a Shelf Take-Down which, at the request of the Demand Holder, is to be in the
form of a registration in which securities of the Company are sold to an Underwriter or Underwriters on a firm commitment basis for reoffering to the public. 
  

	 	3.	The following section shall be added at the end of Section 2 as a new section, 2.1.5: 

“Joint Demand Registration. Notwithstanding anything to the contrary in this Agreement, prior to a person making a demand for
a Demand Registration under either the Riverwood Registration Rights Agreement or this Agreement, as applicable, subsequent to the first Qualified Public Offering, such person shall provide notice (with the information required by Section 2.2
hereof or by Section 3.1(a) of the Riverwood Registration Rights Agreement, respectively), in the case of a demand proposed to be made under the Riverwood Registration Rights Agreement, to the persons with demand registration rights under this
Agreement, or, in the case of a demand proposed to be made under this Agreement, to the persons with demand registration rights under the Riverwood Registration Rights Agreement (the persons receiving such notice, the

 
“Recipients” and the persons sending such notice, the “Senders”). Within 10 business days of receiving such notice, the Recipients may give written
notice (the “Joint Notice”) to the Senders that the Recipients have chosen that such registration be conducted as a joint demand registration (“Joint Demand Registration”) of both the Riverwood Shares
and the Registrable Securities (for purposes of this Section 2.1.5, the “Pegasus Shares”). If the Joint Notice is timely given to the Senders, the Recipients and Senders shall together present a joint demand for a Joint
Demand Registration to the Company. A Joint Demand Registration will not count against the maximum number of Demand Registrations permitted by Section 2.1.1. Upon election of a Joint Demand Registration, the Demand Holders (as defined in the
Riverwood Registration Rights Agreement) of Riverwood Shares as a group and the Demanding Holders of Pegasus Shares as a group requesting securities to be included on such Joint Demand Registration shall have the right to include an equal number of
shares if the offering is underwritten and the managing underwriter or underwriters for the Joint Demand Registration advises that the dollar amount or number of securities requested to be included exceeds the maximum dollar amount or maximum number
of securities that can be sold in such offering without adversely affecting the proposed offering price, the timing, the distribution method or the probability of success of such offering. For the avoidance of doubt, the Joint Demand shall be
considered a Demand Registration of both the Riverwood Shares and the Pegasus Shares, and any shares requested to be included by other holders pursuant to contractual rights would only be included in the registration after all of the requested
Pegasus Shares and Riverwood Shares were included in such registration. Selection of counsel for Selling Demanding Holders (as defined in the Riverwood Registration Rights Agreement) of Riverwood Shares and the Demanding Holders of Pegasus Shares
shall be a joint decision. Should an Underwritten Shelf Takedown be requested with respect to Riverwood Shares or Pegasus Shares, the rights to be included in such Underwritten Shelf Takedown shall be the same as if it were a demand registration
after the first Qualified Public Offering.” 
  

	 	4.	For the avoidance of doubt, Section 2.3 of the Registration Rights Agreement shall be amended by adding the following at the end thereof: 

“Any Pegasus Party may initiate an unlimited number of offerings or sales (which may be underwritten or non-underwritten) of all or
part of the Registrable Securities included on Form S-3 (a “Shelf Take-Down”), and with respect to each Shelf Take-Down, each other holder of Registrable Securities included in a Form S-3 shall be entitled to sell their pro
rata portion of Registrable Securities that they previously requested be included in such Form S-3. Notwithstanding anything herein to the contrary, for the avoidance of doubt, any Shelf Take-Down that is underwritten (other than a Marketed
Underwritten Shelf Take-Down) will not count as a Demand Registration under Section 2.1.1. If such Shelf Take-Down is a Marketed Underwritten Shelf Take-Down, the non-initiating holders of Registrable Securities and other holders with
contractual piggy-back rights will have the right to sell in such Shelf Take-Down their pro rata portion of Registrable Securities that they previously requested be included in such Form S-3 pursuant to, and in accordance with, the provisions
applicable to Piggy-Back Registrations as set forth in Section 2.2. If such Shelf Take-Down is a Non-Marketed Underwritten Shelf Take-Down, none of the non-initiating holders of Registrable Securities nor any other person will have the right to
sell in such Shelf Take-Down any of the Registrable Securities they previously had requested be included on such Shelf Registration Statement.” 

	 	5.	The following shall be added as the new Section 6, and the existing Section 6 shall be renumbered as Section 7: 

 

	 	“6.	Holdback Agreements. 

6.1 No holder of Registrable Securities shall sell, transfer, make any short sale of, grant any option for the purchase of, or enter into
any hedging or similar transaction with the same economic effect as a sale (including sales pursuant to Rule 144) (a “Sale Transaction”) of any Equity Securities of the Company, or any securities convertible into or
exchangeable or exercisable for any such Equity Securities, during the seven (7) day period prior to and the 180 day period beginning on the effective date of the Company’s initial Qualified Public Offering (or such shorter period of time
as is sufficient and appropriate, in the sole discretion of the managing Underwriter) (the “QPO Holdback Period”), except as part of such Qualified Public Offering provided, that the following persons are restricted in
the same manner and for the same duration (A)(i) all of the Company’s affiliates and executive officers and all of the members of the Board of Directors, and (ii) the holders of Riverwood Shares and any successors, assigns and transferees,
and (B) if such persons are selling stockholders in the Company’s initial Qualified Public Offering, (i) the holders of Home Depot Shares and any successors, assigns and transferees and (ii) the holders of Geveran Shares and any
successors, assigns and transferees thereof, in each such case. In connection with any underwritten registrations (other than the initial Qualified Public Offering), no holder of Registrable Securities shall effect any such Sale Transaction during
the seven (7) day period prior to and the 90 day period beginning on the effective date of such offering (or such shorter period of time as is sufficient and appropriate, in the sole discretion of the managing Underwriter) (each, a
“Following Holdback Period”); provided, that the following persons are restricted in the same manner and for the same duration (A) (i) all of the Company’s affiliates and executive officers and all of
the members of the Board of Directors, and (ii) the holders of Riverwood Shares and any successors, assigns and transferees, and (B) if such persons are selling stockholders in the underwritten public offering (other than the initial
Qualified Public Offering), (i) the holders of Home Depot Shares and any successors, assigns and transferees and (ii) the holders of Geveran Shares and any successors, assigns and transferees thereof, in each such case. If (i) the
Company issues an earnings release or other material news or a material event relating to the Company and its subsidiaries occurs, in either case during the last 17 days of the QPO Holdback Period or any Following Holdback Period (as applicable) or
(ii) prior to the expiration of the QPO Holdback Period or any Following Holdback Period (as applicable), the Company announces that it will release earnings results during the 16 day period beginning upon the expiration of such period, then to
the extent necessary for a managing or co managing Underwriter of a registered offering required hereunder to comply with NASD Rule 2711(f)(4) (or any successor rule), the QPO Holdback Period or any Following Holdback Period (as applicable) shall be
extended until 18 days after the earnings release or the occurrence of the material news or event, as the case may be (such period referred to herein as the “Holdback Extension”); provided, that the following persons
are restricted in the same manner and for the same duration: (A)(i) all of the Company’s affiliates and executive officers and all of the members of the Board of Directors, and (ii) the holders of Riverwood Shares and any successors,
assigns and transferees, and (B) if such persons are 

 
selling stockholders in the applicable underwritten offering, (i) the holders of Home Depot Shares and any successors, assigns and transferees and (ii) the holders of Geveran Shares and
any successors, assigns and transferees thereof, in each such case. The Company shall promptly notify the Pegasus Parties of any earnings release, news or event that may give rise to a Holdback Extension. Subject to the provisos included in this
Section 6.1, the Company may impose stop transfer instructions with respect to the Equity Securities (or other securities) subject to the foregoing restriction until the end of such period, including any period of Holdback Extension.

 6.2 The Company (a) shall not effect any public sale or distribution of its Equity Securities, or any securities
convertible into or exchangeable or exercisable for such securities, during the seven (7) day period prior to and during such period of time as may be determined by the Underwriters managing the underwritten registration following the effective
date of any underwritten Demand Registration, a Joint Demand Registration or any underwritten Piggy-Back Registration (not to exceed 180 days in connection with the Company’s initial Qualified Public Offering or 90 days in all other cases,
except in each case as extended during the period of any Holdback Extension), except as part of such underwritten registration or pursuant to registrations on Form S–8 or any successor form and unless the Underwriters managing the registered
public offering otherwise agree in writing, and (b) shall take commercially reasonable efforts to cause each holder of at least 1% of its Equity Securities, or any securities convertible into or exchangeable or exercisable for Equity
Securities, purchased from the Company at any time after the date of this Agreement (other than in a registered public offering) to agree not to effect any public sale or distribution (including sales pursuant to Rule 144) of any such securities
during such period (as extended by any Holdback Extension), except as part of such underwritten registration, if otherwise permitted, unless the Underwriters managing the registered public offering otherwise agree in writing.” 

[Remainder of page intentionally left blank] 

 IN WITNESS WHEREOF, the parties have caused this Amendment to be executed and delivered by
their duly authorized representatives as of the date first written above. 
  

			
	LIGHTING SCIENCE GROUP CORPORATION
		
	By:	 	 /s/ Gregory T. Kaiser

	Name:	 	Gregory T. Kaiser
	Title:	 	Chief Financial Officer
	
	PEGASUS PARTNERS IV, L.P.
		
	By:	 	 Pegasus Investors IV, L.P.,

its general partner

		
	By:	 	 Pegasus Investors IV GP, L.L.C.,
 its general partner

		
	By:	 	 /s/ Steven Wacaster

	Name:	 	Steven Wacaster
	Title:	 	Vice President
	
	LSGC HOLDINGS LLC
		
	By:	 	 Pegasus Partners IV, L.P.,

its managing member

		
	By:	 	 Pegasus Investors IV, L.P.,

its general partner

		
	By:	 	 Pegasus Investors IV GP, L.L.C.,
 its general partner

		
	By:	 	 /s/ Steven Wacaster

	Name:	 	Steven Wacaster
	Title:	 	Vice President

 Signature Page to Amendment to 

Amended and Restated Registration Rights AgreementWaiver No. 2 to Amended and Restated Credit Agreement

 Exhibit 10.1 
 WAIVER NO. 2 
 Dated as of May 31, 2012 

to 
 AMENDED AND
RESTATED 
 CREDIT AGREEMENT 
 Dated as of August 27, 2010 
 THIS WAIVER NO. 2 (this
“Waiver”) is made as of May 31, 2012 (the “Effective Date”) by and among Medical Action Industries Inc., a Delaware corporation (the “Company”), the financial institutions listed on the
signature pages hereof as Lenders and JPMorgan Chase Bank, N.A., as Administrative Agent (the “Administrative Agent’), under that certain Amended and Restated Credit Agreement, dated as of August 27, 2010, by and among the
Company, the financial institutions from time to time party thereto as Lenders (the “Lenders”) and the Administrative Agent (as further amended, restated, supplemented or otherwise modified from time to time, the “Credit
Agreement”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings given to them in the Credit Agreement. 
 WHEREAS, the Company has informed the Lenders that an Event of Default is expected to occur as a result of the Company’s failure to comply with Sections 7.13(a) and 7.13(b) of the
Credit Agreement with respect to the fiscal quarter of the Company ended March 31, 2012 (such failures, the “Specified Defaults”); 
 WHEREAS, the Company has requested that the Lenders and the Administrative Agent agree to waive the Specified Defaults; and 
 WHEREAS, the Lenders and the Administrative Agent have so agreed on the terms and conditions set forth herein; 
 NOW, THEREFORE, in consideration of the premises set forth above, the terms and conditions contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Company, the Lenders and the Administrative Agent hereby agree as follows. 
 1. Waiver. Subject to the
satisfaction of the conditions precedent set forth in Section 3 below, the Lenders hereby waive the Specified Defaults; provided that, this Waiver shall cease being effective on the earliest of (i) June 29, 2012,
(ii) any date on which the Company shall fail to comply with any of the “Reporting Requirement” (as defined below) set forth below, (iii) any date on which the aggregate Revolving Credit Exposures exceed $21,670,000 and
(iv) the occurrence or identification of any Event of Default other than any of the Specified Defaults (such date, the “Waiver Termination Date”). For the avoidance of doubt, (A) on the Waiver Termination Date, unless
otherwise agreed to in writing by the Administrative Agent and the Required Lenders, the limited waiver set forth in the preceding sentence shall be automatically revoked, and the Administrative Agent and Lenders shall have all the rights and
remedies afforded by the Credit Agreement and the other Loan Documents as if such limited waiver had never been granted and (B) prior to the Waiver Termination Date, for all 

 
purposes of the Loan Documents (including, without limitation, Section 5.02 of the Credit Agreement), no Default or Event of Default shall be deemed to have occurred as a result of the
Specified Defaults. 
 2. Reporting Requirements and Amendment to Applicable Margin. (a) Notwithstanding any
provision to the contrary in the Credit Agreement or any other Loan Document, the Company shall deliver to the Administrative Agent and each Lender no later than the first Wednesday following the end of each calendar week ending after the date
hereof until the Waiver Termination Date, a cash flow projection for the Company for the forthcoming thirteen-week period on a week by week basis, substantially in such form as may be approved from time to time by the Administrative Agent in its
sole discretion (such reporting requirement set forth in this Section 2, the “Reporting Requirement”). 
 (b) On and after the Effective Date, notwithstanding any provision to the contrary in the Credit Agreement or any other Loan Document, the definition of Applicable Margin set forth in Section 1.01 of
the Credit Agreement shall be amended and restated in its entirety to read as follows: 
 “Applicable
Margin” shall mean (a) with respect to an Adjusted Libor Loan, 4.00%, (b) with respect to an Alternate Base Rate Loan, 3.00% and (c) with respect to calculation of the unused fee described in Section 3.04(a) hereof,
0.625%. 
 3. Conditions of Effectiveness. The effectiveness of this Waiver is subject to the conditions precedent that
(i) the Administrative Agent shall have received counterparts of (x) this Waiver duly executed by the Company, the Required Lenders and the Administrative Agent, and (y) the Consent and Reaffirmation attached as Exhibit A
hereto duly executed by the Guarantors and (ii) the Administrative Agent shall have received payment and/or reimbursement of the Administrative Agent’s and its affiliates’ reasonable and documented out-of-pocket expenses (including,
to the extent invoiced, reasonable fees and expenses of counsel for the Administrative Agent) in connection with this Waiver. For the avoidance of doubt, delivery of executed counterparts of this Waiver by the Required Lenders and the Administrative
Agent to the Company shall be conclusive evidence that the foregoing conditions precedent have been fully and finally satisfied or waived, and this Waiver has become effective. 

4. Representations and Warranties of the Company. The Company hereby represents and warrants as of the date hereof as follows:

 (a) This Waiver constitutes a legal, valid and binding obligation of the Company and is enforceable against the Company in
accordance with its terms, except to the extent that enforcement may be limited by applicable bankruptcy, reorganization, moratorium, insolvency or similar laws affecting creditors’ rights generally or by equitable principles of general
application, regardless of whether considered in a proceeding in equity or at law. 
 (b) After giving effect to this Waiver, no
Default or Event of Default has occurred and is continuing. 
 (c) After giving effect to this Waiver, the representations and
warranties of the Company and each Guarantor in the Credit Agreement and the other Loan Documents to which each is a party are true and correct in all material respects as of the date hereof (or, if stated to have been made solely as of an earlier
date, were true and correct in all material respects as of such earlier date). 
 5. Cumulative Remedies. Pursuant to the
provisions of Section 10.06 of the Credit Agreement, except as set forth herein, neither any failure nor any delay on the part of any Lender, the Administrative Agent or the Issuing Lender in exercising any right, power or privilege
under the Credit 

  
 2 

 
Agreement or under any other Loan Document shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise of any other right, power or
privilege. The rights, remedies, powers and privileges of the Administrative Agent, the Issuing Lender and the Lenders under the Credit Agreement and under the other Loan Documents are cumulative and are not exclusive of any rights, remedies, powers
and privileges provided by law. Without limiting the generality of the foregoing, the making of a Loan or issuance, amendment, renewal or extension of a Letter of Credit shall not be construed as a waiver of any Default or Event of Default,
regardless of whether the Administrative Agent, any Lender or the Issuing Lender may have had notice or knowledge of such Default or Event of Default at the time. All remedies contained in the Loan Documents or by law as a result of the Specified
Defaults are hereby reserved on behalf of the Administrative Agent, the Issuing Lender and the Lenders following the Waiver Termination Date. Neither the Administrative Agent nor any Lender has agreed to waive or forbear with respect to any of its
rights or remedies concerning any Defaults or Events of Default (other than, until the Waiver Termination Date, the Specified Defaults), which may have occurred or are continuing as of the date hereof or which may occur after the date hereof.

 6. Release. In further consideration of the execution by the Administrative Agent and the Lenders of this Waiver, the
Company and its successors and assigns (collectively, the “Releasors”), hereby confirms that (a) it does not have any grounds, and hereby agrees not to challenge (or to allege or to pursue any matter, cause or claim arising
under or with respect to), in any case based upon acts or omissions of the Administrative Agent or any of the Lenders, the effectiveness, genuineness, validity, collectibility or enforceability of the Credit Agreement or any of the other Loan
Documents, the Obligations, the Liens securing such Obligations, or any of the terms or conditions of any Loan Document and (b) it does not possess and hereby completely, voluntarily, knowingly, and unconditionally releases and forever
discharges the Administrative Agent, each of the Lenders, each of their advisors, professionals and employees, each affiliate of the foregoing and all of their respective successors and assigns (collectively, the “Releasees”), from
any and all claims, actions, suits, and other liabilities, including, without limitation, any so-called “lender liability” claims or defenses (collectively, “Claims”), whether arising in law or in equity, which any of the
Releasors ever had, now has or hereinafter can, shall or may have against any of the Releasees for, upon or by reason of any matter, cause or thing whatsoever from time to time occurred on or prior to the date hereof, in any way concerning, relating
to, or arising from (i) any of the Releasors, (ii) the Secured Obligations, (iii) the Collateral, (iv) the Credit Agreement or any of the other Loan Documents, (v) the financial condition, business operations, business
plans, prospects or creditworthiness of the Company, and (vi) the negotiation, documentation and execution of this Waiver and any documents relating hereto. The Releasors hereby acknowledge that they have been advised by legal counsel of the
meaning and consequences of this release. 
 7. No Implicit Waiver. Except as expressly set forth herein, (i) the
execution, delivery and effectiveness of this Waiver shall neither operate as a waiver of any rights, remedies, powers or privileges of the Administrative Agent, the Issuing Lender or the Lenders under the Credit Agreement or any other Loan
Documents, nor constitute a waiver of any provision of the Credit Agreement nor any other Loan Documents and (ii) except as amended hereby, the Credit Agreement shall remain in full force and effect in accordance with its original terms.

 8. Reference to and Effect on the Credit Agreement. Upon the effectiveness hereof, each reference to the Credit
Agreement in the Credit Agreement or any other Loan Document shall mean and be a reference to the Credit Agreement as amended hereby. 
 9. Governing Law. This Waiver shall be construed in accordance with and governed by the laws of the State of New York. 
 10. Headings. Section headings in this Waiver are included herein for convenience 

  
 3 

 
of reference only and shall not constitute a part of this Waiver for any other purpose. 
 11. Counterparts. This Waiver may be executed by one or more of the parties hereto on any number of separate counterparts, and all of said counterparts taken together shall be deemed to constitute
one and the same instrument. 
 [Signature Pages Follow] 

  
 4 

 IN WITNESS WHEREOF, this Waiver has been duly executed as of the day and year first above
written. 
  

			
	MEDICAL ACTION INDUSTRIES INC.,
	as the Company
		
	By:	 	 /s/ John Sheffield

	Name: John Sheffield
	Title: Chief Financial Officer

  
 Signature Page
to Waiver No. 2 to 
 Amended and Restated Credit Agreement 

Medical Action Industries Inc. 

 
			
	JPMORGAN CHASE BANK, N.A.,
	individually as a Lender, as Issuing Lender and as Administrative Agent
		
	By:	 	 /s/ Alicia Schreibstein

	Name: Alicia Schreibstein
	Title: Vice President

  
 Signature Page
to Waiver No. 2 to 
 Amended and Restated Credit Agreement 

Medical Action Industries Inc. 

 
			
	CITIBANK, N.A.,
	as a Lender
		
	By:	 	 /s/ Bernadette M. Walsh

	Name: Bernadette M. Walsh
	Title: Senior Vice President

  
 Signature Page
to Waiver No. 2 to 
 Amended and Restated Credit Agreement 

Medical Action Industries Inc. 

 
			
	HSBC BANK USA, N.A.,
	as a Lender
		
	By:	 	 /s/ William Conlan

	Name: William Conlan
	Title: Vice President

  
 Signature Page
to Waiver No. 2 to 
 Amended and Restated Credit Agreement 

Medical Action Industries Inc. 

 
			
	 WELLS FARGO BANK, N.A.,

	 as a Lender

		
	By:	 	 /s/ Steven J. Haas

	Name:	 	Steven J. Haas
	Title:	 	Senior Vice President

 Signature Page to Waiver No. 2 to 

Amended and Restated Credit Agreement 
 Medical Action Industries Inc. 

 EXHIBIT A 
 Consent and Reaffirmation 
 Each of the undersigned hereby acknowledges
receipt of a copy of the foregoing Waiver No. 2, dated as of May 31, 2012 (the “Waiver”), by and among Medical Action Industries Inc., a Delaware corporation (the “Company”), the financial institutions
signatory thereto as Lenders, and JPMorgan Chase Bank, N.A., as Administrative Agent (the “Administrative Agent”), with respect to that certain Amended and Restated Credit Agreement (as the same may be amended, restated,
supplemented or otherwise modified from time to time, the “Credit Agreement”) by and among the Company, the financial institutions from time to time party thereto as Lenders and the Administrative Agent. Capitalized terms used in
this Consent and Reaffirmation and not defined herein shall have the meanings given to them in the Credit Agreement. Without in any way establishing a course of dealing by the Administrative Agent or any Lender, each of the undersigned consents to
the Waiver and reaffirms the terms and conditions of the Guaranty and any other Loan Document executed by it, and acknowledges and agrees that the Guaranty and each and every such Loan Document executed by the undersigned in connection with the
Credit Agreement remains in full force and effect and is hereby reaffirmed, ratified and confirmed. 
 Dated: May 31, 2012 

[Signature Page Follows] 

 IN WITNESS WHEREOF, this Consent and Reaffirmation has been duly executed as of the day and
year above written. 
  

			
	MAI ACQUISITION CORP.
		
	By:	 	 /s/ John Sheffield

	Name:	 	John Sheffield
	Title:	 	CFO and Director
	
	MEDEGEN NEWCO, LLC
		
	By:	 	 /s/ John Sheffield

	Name:	 	John Sheffield
	Title:	 	Secretary
	
	MEDEGEN MEDICAL PRODUCTS, LLC
		
	By:	 	 /s/ John Sheffield

	Name:	 	John Sheffield
	Title:	 	Managing Member
	
	500 EXPRESSWAY DRIVE SOUTH LLC
		
	By:	 	 /s/ Paul Meringolo

	Name:	 	Paul Meringolo
	Title:	 	Officer
	
	AVID MEDICAL, INC.
		
	By:	 	 /s/ John Sheffield

	Name:	 	John Sheffield
	Title:	 	CFO and Secretary

 Consent and Reaffirmation to Waiver No. 2 to 

Amended and Restated Credit Agreement 
 Medical Action Industries Inc.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}]]